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matrix, which is regulated by matrix metalloproteinases (MMPs). However, changes in
MMPs associated with AF have not been described previously.
Methods and Results: Left atrial myocardium was obtained from explanted hearts of 16
patients (pts) with heart failure (CHF) undergoing transplantation. A history of persistent
AF was present in 6 pts and the remaining 10 pts served as non-AF controls. Plasma
samples were obtained from 16 separate pts without CHF, including 6 undergoing cardio-
version for persistent AF and 10 controls matched for age, gender, left ventricular size
and function. Myocardial MMP-2 and –9 levels, two MMP species implicated in cardiac
remodeling, were determined by zymography and plasma MMP-2 and -9 levels were
measured using enzyme linked immunosorbent assays (Table, *p<0.05 vs. non-AF).
MMP-9 levels were increased in both the myocardium and the plasma in AF pts, whereas
myocardial and plasma MMP-2 levels were similar between groups.
Conclusions: AF is associated with alterations in the myocardial and plasma levels of
the same MMP species, despite evaluating 2 very different pt populations. These findings
suggest that changes in plasma MMP levels may provide a biomarker to detect atrial
structural changes associated with AF.
1014-226 Measurement of Atrial Function Before and Immediately 
After Cardioversion for Atrial Fibrillation Using a 
Combined Transesophageal Probe for Cardioversion 
and Echocardiography
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Erasmus Medical Center, Rotterdam, The Netherlands, New York University School of 
Medicine, New York, NY
Background: Early cardioversion (ECV) after exclusion of a clot by transesphageal
echocardiography (TEE) is a proven strategy. Transesophageal cardioversion (TEC) has
been studied previously and is safe and efficacious. Combining TEE and TEC has the
potential benefit of single need for sedation and offers the opportunity to study left atrial
(LA), transmitral and LA appendage (LAA) flow during and immediately after ECV.
Methods: A custom-made combined TEC and TEE probe was used. After sedation with
weight adjusted Diazepam TEE was done. Measurements of pulmonary vein (PV) flow,
LAA emptying velocity and transmitral flow were done. Presence of clot or spontaneous
echo contrast (smoke) was scored. After exclusion of clot TEC was done after weight
adjusted Ethomidate and using a step up protocol 20-30-50 Joules biphasic shock. All
echocardiographic measurements were repeated 1 and 5 minutes after ECV.
Results: 20 Patients were included in this study (6 female, mean age 63 y (37-80y),
mean BSA 1.81 m2 (1.61-2.60m2)). The duration of AF was unknown in most patients
and in none clot was seen before TEC. Mean LA dimension 49.4 mm (SD 7.07). Sinus
rhythm was achieved in 19/20 patients. Mean transmitral peak E wave velocity decreased
from 73.2 cm/s, to 67.4 cm/s and 65.9 cm/s. Mean peak A wave velocity 33.9 cm/s (17-55
cm/s) at 1 min., and 37.1 cm/s (20-75 cm/s) at 5 min..4 patients had no A wave at 1 min,
and 2 had no A wave at 5 min despite sinus rhythm. Mean peak LAA velocity decreased
from 40.4 cm/s to 29.6 cm/s at 1 min. and to 27.6 cm/s at 5 min. after TEC. In 3/20
patients smoke was present before TEC andSmoke appeared in 8/20 patients immedi-
ately after ECV.
Conclusion: Combining TEE and TEC is efficacious and allows to study intra-atrial flow
during and after ECV. Atrial stunning was obvious despite the use of very low energy. The
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1015-215 Improved Electrocardiographic Detection of Left 
Ventricular Hypertrophy in Women: Validation by 
Cardiovascular Magnetic Resonance
Michael L. Chuang, Yoram Ariel, Carol J. Salton, Kraig V. Kissinger, Patricia A. Arand, 
Lois A. Goepfert, Robert A. Warner, Warren J. Manning, Beth Israel Deaconess Medical 
Center, Boston, MA, Inovise Medical, Inc, Newberg, OR
Sensitivity of the ECG for left venticular hypertrophy (LVH) is poor when compared to
echocardiography, but echo accuracy is decreased with poor echo windows or distorted
ventricular shape. To more accurately assess ECG performance, we compared the ECG
to volumetric cardiovascular magnetic resonance (CMR) and investigated whether using
multiple gender-specific ECG criteria improves LVH detection in women.
METHODS: 192 consecutive patients (70 women, 122 men, 50±15 years), underwent
12-lead ECG and contiguous multislice SSFP CMR (TR=3.2ms, TE=1.6ms, FA=60º,
1.92-mm2 x10mm voxels, 1.5-T Philips). Patients were classified as LVH+ or LVH- based
on published CMR criteria (LV mass index >=74.7 g/m2, women; >=95.0 g/m2, men).
Multiple ECG criteria for LVH were compared to CMR, including Sokolow-Lyon (SL); gen-
der-specific Cornell Voltage (CV) and Cornell Product (CP); 3 commerical algorithms
(C1, C2, C3); and an algorithm (Audicor) using multiple gender specific LVH criteria.
RESULTS: Prevalence of CMR LVH was 13% in women and 23% in men (p=NS). The
Table shows ECG sensitivity, specificity and positive and negative predictive values
(Sens, Spec, PPV, NPV, %) by gender.
CONCLUSION: Commonly used ECG algorithms have high specificity regardless of gen-
der but modest sensitivity for LVH in men and poor sensitivity in women. Use of multiple
gender-specific ECG criteria (Audicor) for LVH improves sensitivity in women to a level
comparable to that for men while maintaining high specificity and superior PPV and NPV.
1015-216 ST Depression Versus T Wave Amplitude on the Resting 
Electrocardiogram: Which Is the Better Predictor of 
Cardiovascular Mortality?
James Beckerman, Takuya Yamazaki, Jonathan Myers, Sung Chun, Paul Wang, Victor 
Froelicher, Stanford University, Stanford, CA, VA Palo Alto Health Care System, Palo 
Alto, CA
Background: ST depression and T wave amplitude abnormalities are known to be inde-
pendent predictors of cardiovascular death, but a direct comparison between them has
not been described.
Methods: Analyses were performed on the first electrocardiogram digitally recorded on
46,950 consecutive patients at the Palo Alto Veterans Affairs Medical Center since 1987.
Females and patients with electrocardiograms exhibiting bundle branch block, left ven-
tricular hypertrophy, electronic pacing, diagnostic Q waves, or Wolff-Parkinson-White
syndrome were excluded, leaving 31,074 male patients for analysis (mean age 55 ± 14).
There were 1,878 (6.0%) cardiovascular deaths (mean follow-up of 6 ± 4 years). Electro-
cardiograms were classified using Minnesota code according to degree of ST depression
and T wave abnormality, and the nine possible combinations of ST segment and T wave
abnormalities were recoded for analysis.
Results: After adjusting for age and heart rate in a Cox regression model, the combina-
tion of major abnormalities in ST segments and T waves carried the greatest hazard (3.2
[CI 2.7-3.8]). Minor ST depression combined with more severe T wave abnormalities car-
ried a hazard of 3.1 (CI 2.5-3.7), whereas minor T wave abnormalities combined with
more severe ST depression carried a hazard of only 1.9 (CI 1.6-2.3).
Conclusion: While both ST segment depression and abnormal T wave amplitude are
clinically important, T wave abnormalities appear to be more highly associated with car-
diovascular mortality.
1015-217 Holter-Based Risk Stratifiers May Increase Cost-
Effectiveness of Defibrillator Therapy in MADIT II-Like 
Patients
Dan Wichterle, Jan Simek, John Camm, Marek Malik, General University Hospital, 
Prague, Czech Republic, St. George's Hospital Medical School, London, United Kingdom
Background: Both prevalent low-frequency oscillation of heart rate (PLF) and turbulence
slope (TS) are powerful postinfarction risk stratifiers. We investigated the predictive
power of their combination in the subpopulation of placebo arm of EMIAT trial defined by
LVEF < 30%.
Methods: PLF and TS were calculated by standard methods. Cut-off values of PLF > 0.1
Hz and TS < 2.5 ms/RR were used as previously established. Two composite risk stratifi-
Mean±SD. IOD: Integrated Optical Density
Myocardium (IOD) Plasma (ng/mL)
Non-AF AF Non-AF AF
MMP-2 68±24 83±11 1251±373 1183±278
MMP-9 29±12 51±22* 22±14 80±54*
ECG vs. CMR LVH
SL CV CP C1 C2 C3 Audicor
Women: Sens/Spec 11/95 11/90 11/100 11/95 0/95 22/92 44/92
Men: Sens/Spec 50/85 33/99 61/90 46/82 46/81 68/82 54/90
Women: PPV/NPV 25/88 14/87 100/88 25/88 0/87 29/89 44/92
Men: PPV/NPV 50/85 91/84 65/89 43/84 42/84 53/90 63/87
